These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28322129)

  • 1. Including historical data in the analysis of clinical trials: Is it worth the effort?
    van Rosmalen J; Dejardin D; van Norden Y; Löwenberg B; Lesaffre E
    Stat Methods Med Res; 2018 Oct; 27(10):3167-3182. PubMed ID: 28322129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust meta-analytic-predictive priors in clinical trials with historical control information.
    Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
    Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel power prior approach for borrowing historical control data in clinical trials.
    Shi Y; Li W; Liu GF
    Stat Methods Med Res; 2023 Mar; 32(3):493-508. PubMed ID: 36601652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
    Hupf B; Bunn V; Lin J; Dong C
    Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified power prior with multiple historical trials for binary endpoints.
    Banbeta A; van Rosmalen J; Dejardin D; Lesaffre E
    Stat Med; 2019 Mar; 38(7):1147-1169. PubMed ID: 30360016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
    Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
    BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian hypothesis testing with frequentist characteristics in clinical trials.
    Quan H; Zhang B; Lan Y; Luo X; Chen X
    Contemp Clin Trials; 2019 Dec; 87():105858. PubMed ID: 31669448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian borrowing from historical control data in a vaccine efficacy trial.
    Peng L; Jin J; Chambonneau L; Zhao X; Zhang J
    Pharm Stat; 2023; 22(5):815-835. PubMed ID: 37226586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dynamic power prior for borrowing historical data in noninferiority trials with binary endpoint.
    Liu GF
    Pharm Stat; 2018 Feb; 17(1):61-73. PubMed ID: 29125220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size calculation for clinical trials analyzed with the meta-analytic-predictive approach.
    Qi H; Rizopoulos D; van Rosmalen J
    Res Synth Methods; 2023 May; 14(3):396-413. PubMed ID: 36625478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Historical controls in clinical trials: a note on linking Pocock's model with the robust mixture priors.
    Callegaro A; Galwey N; Abellan JJ
    Biostatistics; 2023 Apr; 24(2):443-448. PubMed ID: 37057610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using horseshoe prior for incorporating multiple historical control data in randomized controlled trials.
    Ohigashi T; Maruo K; Sozu T; Gosho M
    Stat Methods Med Res; 2022 Jul; 31(7):1392-1404. PubMed ID: 35379046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elastic meta-analytic-predictive prior for dynamically borrowing information from historical data with application to biosimilar clinical trials.
    Zhang W; Pan Z; Yuan Y
    Contemp Clin Trials; 2021 Nov; 110():106559. PubMed ID: 34506959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison Between a Meta-analytic Approach and Power Prior Approach to Using Historical Control Information in Clinical Trials With Binary Endpoints.
    Isogawa N; Takeda K; Maruo K; Daimon T
    Ther Innov Regul Sci; 2020 May; 54(3):559-570. PubMed ID: 33301135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence synthesis from aggregate recurrent event data for clinical trial design and analysis.
    Holzhauer B; Wang C; Schmidli H
    Stat Med; 2018 Mar; 37(6):867-882. PubMed ID: 29152777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilizing shared internal control arms and historical information in small-sized platform clinical trials.
    Jiao F; Tu W; Jimenez S; Crentsil V; Chen YF
    J Biopharm Stat; 2019; 29(5):845-859. PubMed ID: 31462131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporating historical two-arm data in clinical trials with binary outcome: A practical approach.
    Feißt M; Krisam J; Kieser M
    Pharm Stat; 2020 Sep; 19(5):662-678. PubMed ID: 32227680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Power priors based on multiple historical studies for binary outcomes.
    Gravestock I; Held L
    Biom J; 2019 Sep; 61(5):1201-1218. PubMed ID: 30325059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior.
    Qi H; Rizopoulos D; Lesaffre E; van Rosmalen J
    Pharm Stat; 2022 Sep; 21(5):818-834. PubMed ID: 35128780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summarizing historical information on controls in clinical trials.
    Neuenschwander B; Capkun-Niggli G; Branson M; Spiegelhalter DJ
    Clin Trials; 2010 Feb; 7(1):5-18. PubMed ID: 20156954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.